UnitedHealth is Down Big Over 3 Months: A Big Bank Says 40% Gains to Come After Raising Their Target

UnitedHealth fell 10.62% over three months to about $377.64 amid membership declines, including 935,000 fewer Medicare Advantage members since the start of the year, despite beating Q3 adjusted EPS estimates ($4.69 vs. $4.15) and raising full-year adjusted EPS guidance to at least $20.50. Morgan Stanley raised its target from $468 to $529, implying 40.1% upside; the consensus target is $480.60, or 27.3% above the share price. Optum Health operating earnings rose to $735 million from $41 million, but the bullish case depends on margin recovery offsetting enrollment losses and related regulatory and legal risks.

Analysis

The market is pricing an execution problem, not simply a temporary dip: lost members matter if they weaken fixed-cost absorption or signal that plan benefits, pricing, or distribution are less competitive. But enrollment is not the right standalone scorecard. If UnitedHealth is exiting underperforming markets, lower membership alongside sustained margin improvement could be value-accretive; the key test is whether Optum’s recovery persists after restructuring effects and whether UnitedHealthcare’s margin holds without favorable reserve development.

The main second-order risk is a feedback loop: weaker Medicare Advantage economics could force less attractive benefits or pricing, further impairing retention and Star Ratings, while rivals such as Elevance Health and Humana may gain selectively. That transfer is not automatic; competitor enrollment growth could bring less-profitable members or trigger competitive repricing. CMS ratings and Justice Department outcomes have 1–3 month headline risk, but their enrollment and revenue effects can lag into subsequent plan years. Over 6–18 months, sustainable Optum profitability and stable MA unit economics matter more than headline EPS beats.

The bullish case is plausible but consensus positioning is a vulnerability: uniformly positive analyst ratings and rising estimates leave less protection if membership or costs disappoint. Treat Morgan Stanley’s target as a scenario, not evidence of fair value. Near term, absent a membership or regulatory catalyst, no need to chase a recovery; a confirmation-based long offers better asymmetry than assuming mean reversion.

Key Decisions for Investors

• UNH: consider a staged long only after the next membership update shows stabilization and Optum operating earnings remain durable. The current price is below the article’s cited 50-day average ($388.46); reclaiming it could provide confirmation. A close below the cited 200-day average ($357.79), or renewed deterioration in MA retention/cost trends, would falsify the setup and warrant reassessment.
• For a 1–3 month event window, keep UNH exposure modest ahead of CMS, DOJ, and membership updates. Track Star Ratings and reserve development separately from underlying medical-cost trends; a reported margin improvement dependent on reserve releases is not confirmation.
• Do not use ELV or HUM as automatic hedges: their MA mix and exposure may differ, and displaced UNH members are not guaranteed to transfer profitably. If seeking sector-neutral exposure, first compare plan-level enrollment, ratings, and unit economics; otherwise prefer a smaller outright UNH position.
• Watch the next guidance and earnings revisions over 6–18 months: persistent Optum improvement plus stable MA economics supports adding; falling estimates, continued member attrition, or evidence of benefit/pricing pressure argues against the long even if the headline valuation appears inexpensive.